Genelux (GNLX)

• Market cap: $156M
• 1 day: 1.22%
• 5 days: -7.98%
• 1 month: -20.95%
• 3 months: 6.14%
• 6 months: 37.42%
• Year to date: 72.2%
• 1 year: 72.92%
• 5 years: -32.52%
• 10 years: -32.52%
• Sector: Healthcare
• Industry: Biotechnology

About: Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.

Employees: 24